Prosperity Consulting Group’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Prosperity Consulting Group's REGN Position: Q2 2026 in Review
Prosperity Consulting Group increased its Regeneron Pharmaceuticals (REGN) stake by 12% in Q2 2026, buying an estimated $28.6K and bringing the position to 402 shares worth $251K. The position accounts for 0.01% of the portfolio, ranked #535.
Prosperity Consulting Group first reported a position in REGN in Q3 2024 and has held it in 4 quarters since. The position peaked at $278K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Prosperity Consulting Group held 402 shares of Regeneron Pharmaceuticals worth $251K as of Q2 2026.
- Prosperity Consulting Group bought 42 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $28.6K.
- Regeneron Pharmaceuticals made up 0.01% of Prosperity Consulting Group's portfolio in Q2 2026, its #535 holding.
- Prosperity Consulting Group first reported a position in Regeneron Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
- Prosperity Consulting Group's Regeneron Pharmaceuticals position peaked at $278K in Q1 2026.
- 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Prosperity Consulting Group's 13F filing for Q2 2026, filed 13 Aug 2026.